ALAMEDA, Calif.--(BUSINESS WIRE)--Nov. 30, 2017--
BioTime, Inc. (NYSE American: BTX), a late-stage, clinical biotechnology
company developing and commercializing products addressing degenerative
diseases, today announced that detailed data from the successful pivotal
trial of Renevia® in Europe will be presented at
the International Federation Adipose Therapeutics and Science (IFATS)
conference on November 30, 2017. The Renevia® program will be
presented by primary investigator Ramon Llull, MD, PhD, Director of Stem
Europe Mallorca Center, Mallorca, Spain at the “Plenary Session 2 -
Clinical Studies with SVF”.
Renevia® is an investigational medical device that is being
developed as an alternative for whole adipose tissue transfer (fat
grafting) procedures. Renevia’s® hydrogel polymer network
provides the requisite amino acid sequences for adipose stromal vascular
cell attachment and may support proliferation, localization and
adipogenic differentiation. Renevia® is part of the Hystem®
hydrogel family of proprietary injectable matrices, which are designed
to facilitate the survival and growth of transplanted cells.
About BioTime, Inc.
BioTime is a late stage clinical biotechnology company focused on
developing and commercializing products addressing degenerative
diseases. The Company’s current clinical programs are targeting three
primary sectors, aesthetics, ophthalmology and cell and drug delivery.
Its clinical programs are based on two platform technologies:
pluripotent cells, which can become any type of cell in the human body,
and cell/drug delivery. Renevia®, a cell delivery product,
met its primary endpoint in an EU pivotal clinical trial for the
treatment of facial lipoatrophy in HIV patients earlier this year.
Submission for approval of Renevia® in the EU is expected to
be early 2018, with possible approval and commercial launch in 2018.
There were no device related serious adverse events reported. OpRegen®,
a retinal pigment epithelium transplant therapy, is in a Phase I/IIa
multicenter trial for the treatment of dry age-related macular
degeneration, the leading cause of blindness in developing countries.
There were no related serious adverse events reported. BioTime also has
significant equity holdings in two publicly traded companies, Asterias
Biotherapeutics, Inc. (NYSE American: AST) and OncoCyte
Corporation (NYSE American: OCX), and a private company, AgeX
BioTime common stock is traded on the NYSE American and TASE under the
symbol BTX. For more information, please visit www.biotime.com or
connect with the company on Twitter, LinkedIn, Facebook, YouTube,
To receive ongoing BioTime corporate communications, please click on the
following link to join the Company’s email alert list: http://news.biotime.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171130005347/en/
Source: BioTime, Inc.
David Nakasone, 510-871-4188
JQA Partners, Inc.
Jules Abraham, 917-885-7378